Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB

Cancer

Last data update: Mar 20, 2023. (Total: 58791 Documents since 2012)
   dataset      
Filtered By:

Previous    

Records 1 - 30 (of 83 Records)

Next

Query Trace: Lung Cancer[original query]>>Evidence Synthesis [Product Type]
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
Edurne Arriola et al. JCO precision oncology 2023 7e2200546
Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
Yi-Ling Tsai et al. Value in health regional issues 2023 3548-56
Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
Hongbin Dai et al. Frontiers in medicine 2023 101122731
Association of Reported Candidate Monogenic Genes With Lung Cancer Risk.
Andrew S Rifkin et al. Clinical lung cancer 2023
Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
Lemmon Christopher A et al. JCO precision oncology 2023 7e2200294
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
Mikhael Peter G et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 JCO2201345
Diagnostic test accuracy of artificial intelligence-based imaging for lung cancer screening: A systematic review and meta-analysis.
Thong Lay Teng et al. Lung cancer (Amsterdam, Netherlands) 2022 1764-13
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez Luis et al. Journal of managed care & specialty pharmacy 2022 1-15
Multiple mutations in the EGFR gene in lung cancer: a systematic review.
Castañeda-González Juan Pablo et al. Translational lung cancer research 2022 11(10) 2148-2163
Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis.
Palmieri Maria et al. Frontiers in genetics 2022 131015161
Reclassification of risk of malignancy with Percepta Genomic Sequencing Classifier following nondiagnostic bronchoscopy.
Raval Abhijit A et al. Respiratory medicine 2022 204106990
The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
Wang Bi-Cheng et al. PloS one 2022 17(10) e0275919
Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer.
Simons Martijn J H G et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2022
The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Luo Xia et al. Frontiers in pharmacology 2022 13935581
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.
Ezeife Doreen A et al. Therapeutic advances in medical oncology 2022 1417588359221112696
Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands.
Wolff Henri B et al. JCO precision oncology 2022 6e2200201
Diagnostic Value and Cost-effectiveness of Next Generation Sequencing-based Testing for Treatment of Patients with Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer in the US.
Zou Denise et al. The Journal of molecular diagnostics : JMD 2022
IPRS: Leveraging Gene-Environment Interaction to Reconstruct Polygenic Risk Score.
Tang Yingdan et al. Frontiers in genetics 2022 13801397
Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
Vanderpoel Julie et al. Journal of medical economics 2022 1-17
Computer-aided detection of pulmonary nodules based on convolutional neural networks: a review.
Min Yuqin et al. Physics in medicine and biology 2022
Lung cancer risk prediction models based on pulmonary nodules: A systematic review.
Wu Zheng et al. Thoracic cancer 2022
Diagnostic value of microRNA-148/152 family in non-small-cell lung cancer (NSCLC): A systematic review and meta-analysis.
Cheng Long et al. Medicine 2022 100(48) e28061
Accounting for EGFR mutations in epidemiological analyses of non-small cell lung cancers: Examples based on the International Lung Cancer Consortium data.
Schmid Sabine et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2022
Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
Harvey Michael J et al. JCO precision oncology 2022 51611-1624
Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China.
Shi Yafei et al. Annals of translational medicine 2021 9(18) 1480
Gene-Guided Treatment Decision-Making in Non-Small Cell Lung Cancer - A Systematic Review.
Saarenheimo Jatta et al. Frontiers in oncology 2021 11754427
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons Martijn J H G et al. PharmacoEconomics 2021
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Cruz Barbara D et al. Oncology and therapy 2021
Potential value of MicroRNA-21 as a biomarker for predicting the prognosis of patients with breast cancer: A protocol for meta-analysis and bioinformatics analysis.
Ding Yunfeng et al. Medicine 2021 100(22) e25964
Diagnostic accuracy of deep learning in medical imaging: a systematic review and meta-analysis.
Aggarwal Ravi et al. NPJ digital medicine 2021 4(1) 65
TOP